Revelation Biosciences GAAP EPS of -$5.92 (NASDAQ:REVB)

Revelation Biosciences reported a Q3 GAAP EPS of -$5.92. The company had $9.1M in cash as of September 30, 2026, down from $10.7M at the end of 2025, according to the company.

Original reporting
Published Nov 6, 2026, 8:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$REVB
Bearish
medium confidence
Mentioned
$REVB
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$REVBBearishLow
01

Why it matters

The earnings miss and cash reduction are likely to trigger short‑term selling pressure, especially in a thinly traded micro‑cap environment.

02

Market read

First‑time earnings disclosure for a micro‑cap biotech; negative results suggest near‑term downside risk.

03

What to watch

Potential upcoming clinical trial milestones or partnership announcements not covered in this brief could offset the negative earnings.

Relevance 6/10Novelty 5/10Timing: pre-market today

Background

Revelation Biosciences (NASDAQ:REVB) released its Q3 2026 earnings, showing a GAAP loss of $5.92 per share and a cash balance decline from $10.7M to $9.1M.

Company-level read

Ticker impact

$REVBBearishMedium confidence
Context

Q3 2026 GAAP EPS reported at -$5.92 and cash down to $9.1M, first disclosure of the quarter's results.

Expected impact

downward pressure as investors price in the loss per share and reduced cash balance

Evidence & confidence

The press release provides the first earnings numbers, showing a sizable loss and a cash decline, which typically triggers sell pressure for a micro‑cap biotech.

Market effects

May weigh on other small‑cap biotech stocks as investors reassess cash runway expectations.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact given the company's size and niche focus.

Counterpoint

If the loss reflects a strategic R&D investment, the stock could be undervalued relative to future pipeline potential.

Key entities

  • Revelation Biosciences

    Biotech firm listed on NASDAQ under ticker REVB.

Related articles

$REVBLow

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.

$LUVUMed

Luvu Brands, Inc.: Luvu Brands Reports First Quarter Fiscal 2027 Results: 10% Net Sales Growth, Wholesale Sales Up 12%

Luvu Brands (LUVU) reported Q1 FY2027 results with net sales up 10% to $6.78M, wholesale sales up 12.3% to $4.72M, and direct-to-consumer sales up 5.3% to $2.06M. Gross profit fell 10.1% to $1.78M due to higher freight and labor costs, resulting in an operating loss of $332K and a net loss of $365K. Cash from operations increased to $120K, and cash reserves were $1.02M.